Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the

Related Keywords

National Taiwan University ,T Ai Pei ,Taiwan ,Japan ,Tokyo ,Texas ,United States ,Singapore ,Belgium ,National Taiwan University Hospital ,California ,South Korea ,London ,City Of ,United Kingdom ,Han ,Taiwanese ,Mo Chiu ,Marielle Herzog ,Department Of Internal Medicine ,Volitionrx Limited ,Linkedin ,Twitter ,Exchange Commission ,Youtube ,Million Taiwanese Screening Program ,Securities Exchange ,Facebook ,Eiken Chemical Co Ltd ,Fecal Immunochemical Test ,Professor Han Mo Chiu ,Development Director ,Internal Medicine ,Cancers Symposium ,World Health Organization International Agency ,One Million Taiwanese Screening ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,Tncen ,Mex Vnrx ,West Southwest ,United States Of America ,North America ,